{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-056160","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2025-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.168118+00:00","generated_at":"2026-05-19T23:44:56.474735+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sagimet partner Ascletis reports positive Phase 3 acne results for denifanstat; Sagimet starts Phase 1 of TVB-3567","bullets":["Denifanstat (50mg once daily) met all primary and secondary endpoints vs placebo in Phase 3 acne trial (n=480) in China.","Treatment success (IGA) 33.2% denifanstat vs 14.6% placebo (p<0.0001); total lesion count change −57.4% vs −35.4%.","Denifanstat well-tolerated; TEAEs comparable to placebo, only dry skin (6.3%) and dry eye (5.9%) above 5%.","Ascletis plans to submit denifanstat for approval to China's NMPA; Sagimet initiated Phase 1 of TVB-3567 for US acne.","Oral FASN inhibition offers novel mechanism for moderate-to-severe acne, a condition affecting 640M+ globally."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-056160","json":"https://secwatch.observer/filing/0001104659-25-056160.json","markdown":"https://secwatch.observer/filing/0001104659-25-056160.md","text":"https://secwatch.observer/filing/0001104659-25-056160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925056160/0001104659-25-056160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925056160/tm2517101d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T23:44:56.474735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}